Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel. more
Time Frame | RDHL | Sector | S&P500 |
---|---|---|---|
1-Week Return | -11.82% | -3.39% | 0.2% |
1-Month Return | 2.43% | -1.92% | 2.72% |
3-Month Return | -30.75% | -10.54% | 7.31% |
6-Month Return | -27.7% | -4.47% | 10.44% |
1-Year Return | -76.52% | 4.06% | 27.53% |
3-Year Return | -99.73% | 0.94% | 30.88% |
5-Year Return | -99.88% | 36.67% | 89.21% |
10-Year Return | -99.94% | 102.87% | 199.95% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 6.29M | 64.36M | 85.76M | 61.80M | 6.51M | [{"date":"2019-12-31","value":7.34,"profit":true},{"date":"2020-12-31","value":75.05,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":72.06,"profit":true},{"date":"2023-12-31","value":7.59,"profit":true}] |
Cost of Revenue | 2.26M | 36.89M | 49.41M | 33.34M | 3.46M | [{"date":"2019-12-31","value":4.57,"profit":true},{"date":"2020-12-31","value":74.67,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":67.48,"profit":true},{"date":"2023-12-31","value":7,"profit":true}] |
Gross Profit | 4.03M | 27.47M | 36.35M | 28.46M | 3.05M | [{"date":"2019-12-31","value":11.09,"profit":true},{"date":"2020-12-31","value":75.56,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":78.3,"profit":true},{"date":"2023-12-31","value":8.4,"profit":true}] |
Gross Margin | 64.09% | 42.68% | 42.39% | 46.06% | 46.89% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":66.59,"profit":true},{"date":"2021-12-31","value":66.14,"profit":true},{"date":"2022-12-31","value":71.86,"profit":true},{"date":"2023-12-31","value":73.16,"profit":true}] |
Operating Expenses | 47.23M | 91.15M | 117.49M | 71.31M | (9.56M) | [{"date":"2019-12-31","value":40.2,"profit":true},{"date":"2020-12-31","value":77.58,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":60.69,"profit":true},{"date":"2023-12-31","value":-8.14,"profit":false}] |
Operating Income | (43.20M) | (63.68M) | (81.14M) | (42.84M) | 12.63M | [{"date":"2019-12-31","value":-342,"profit":false},{"date":"2020-12-31","value":-504.15,"profit":false},{"date":"2021-12-31","value":-642.3,"profit":false},{"date":"2022-12-31","value":-339.17,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Total Non-Operating Income/Expense | 902.00K | (25.06M) | (33.19M) | (70.07M) | 9.16M | [{"date":"2019-12-31","value":9.85,"profit":true},{"date":"2020-12-31","value":-273.55,"profit":false},{"date":"2021-12-31","value":-362.26,"profit":false},{"date":"2022-12-31","value":-764.83,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (42.30M) | (76.17M) | (97.74M) | (71.67M) | 23.95M | [{"date":"2019-12-31","value":-176.62,"profit":false},{"date":"2020-12-31","value":-318.02,"profit":false},{"date":"2021-12-31","value":-408.08,"profit":false},{"date":"2022-12-31","value":-299.22,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income Taxes | 1.33M | 12.84M | 16.57M | (12.42M) | (2.00) | [{"date":"2019-12-31","value":8.03,"profit":true},{"date":"2020-12-31","value":77.53,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-74.99,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (43.63M) | (89.02M) | (114.31M) | (59.24M) | 23.95M | [{"date":"2019-12-31","value":-182.17,"profit":false},{"date":"2020-12-31","value":-371.65,"profit":false},{"date":"2021-12-31","value":-477.25,"profit":false},{"date":"2022-12-31","value":-247.35,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income From Continuous Operations | (42.30M) | (76.17M) | (97.74M) | (71.67M) | 23.92M | [{"date":"2019-12-31","value":-176.89,"profit":false},{"date":"2020-12-31","value":-318.5,"profit":false},{"date":"2021-12-31","value":-408.7,"profit":false},{"date":"2022-12-31","value":-299.67,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (43.63M) | (89.02M) | (114.31M) | (59.24M) | 23.92M | [{"date":"2019-12-31","value":-182.45,"profit":false},{"date":"2020-12-31","value":-372.21,"profit":false},{"date":"2021-12-31","value":-477.97,"profit":false},{"date":"2022-12-31","value":-247.72,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
EPS (Diluted) | (1.45) | (2.10) | (2.10) | (0.90) | (1.54) | [{"date":"2019-12-31","value":-145,"profit":false},{"date":"2020-12-31","value":-210,"profit":false},{"date":"2021-12-31","value":-210,"profit":false},{"date":"2022-12-31","value":-90,"profit":false},{"date":"2023-12-31","value":-154.11,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
RDHL | |
---|---|
Cash Ratio | 0.25 |
Current Ratio | 0.96 |
Quick Ratio | 0.78 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
RDHL | |
---|---|
ROA (LTM) | -44.88% |
ROE (LTM) | -1708.61% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
RDHL | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.90 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.10 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
RDHL | |
---|---|
Trailing PE | NM |
Forward PE | 1428.57 |
P/S (TTM) | 2.47 |
P/B | 150.31 |
EV/R | 0.66 |
EV/Ebitda | 0.30 |
PEG | NM |
Redhill Biopharma Ltd (RDHL) share price today is $7.095
Yes, Indians can buy shares of Redhill Biopharma Ltd (RDHL) on Vested. To buy Redhill Biopharma Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RDHL stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Redhill Biopharma Ltd (RDHL) via the Vested app. You can start investing in Redhill Biopharma Ltd (RDHL) with a minimum investment of $1.
You can invest in shares of Redhill Biopharma Ltd (RDHL) via Vested in three simple steps:
The 52-week high price of Redhill Biopharma Ltd (RDHL) is $40.5. The 52-week low price of Redhill Biopharma Ltd (RDHL) is $6.34.
The price-to-earnings (P/E) ratio of Redhill Biopharma Ltd (RDHL) is
The price-to-book (P/B) ratio of Redhill Biopharma Ltd (RDHL) is 150.31
The dividend yield of Redhill Biopharma Ltd (RDHL) is 0.00%
The market capitalization of Redhill Biopharma Ltd (RDHL) is $9.17M
The stock symbol (or ticker) of Redhill Biopharma Ltd is RDHL